Previous 10 | Next 10 |
IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) second...
AbbVie (NYSE: ABBV ) unit Allergan has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of DARPin drug abicipar pegol for the treatment of neovascular age-related macular degeneration (wet AMD). More news on: AbbVie Inc., Molecul...
Investment Thesis Iveric Bio 1-year share price performance. Source: Trading View Iveric Bio's ( ISEE ) stock may have spiked last week - gaining 78% to reach $6.32 - but investors who have been following the stock for some time will be aware that this could mark the start of a len...
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the closing of its underwritten public offering of 28,503,220 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock, pre-funded warrants to purcha...
Urban One (NASDAQ: UONE ) -17% . More news on: Urban One, Inc., Beasley Broadcast Group, Inc., LiveXLive Media, Inc., Stocks on the move, , Read more ...
After reporting 18-month results from a phase 3 trial evaluating the drug Zimura in geographic atrophy on June 15, Iveric Bio (NASDAQ: ISEE) is tapping investors for more cash, increasing the likelihood its cash stockpile can last it through Zimura's clinical-stage development. In an updat...
Gainers: Alpine Immune Sciences (NASDAQ: ALPN ) +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...
IVERIC bio (NASDAQ: ISEE ) has priced its public offering of 24,535,720 common shares at $4.10/share and, in lieu of common stock, pre-funded warrants to purchase 1,914,280 common shares at $4.099/pre-funded warrant. More news on: IVERIC bio, Inc., Healthcare stocks news, , Read more...
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 24,535,720 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock, pre-funded warrants to...
Gainers: ELOX +52.1% . ORN +17.7% . TMBR +8.5% . ABM +8.0% . DADA +7.2% . More news on: Eloxx Pharmaceuticals, Inc., Orion Group Holdings, Inc., Timber Pharmaceuticals, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...